Federal Circuit Upholds Decision Against Teva Pharmaceuticals in Orange Book Patent Listing Dispute

The Federal Circuit recently denied Teva Pharmaceuticals’ request for an en banc rehearing concerning a panel decision related to the improper listing of its asthma inhaler patents. This appeal involved the listing of these patents on the U.S. Food and Drug Administration’s Orange Book, a crucial database for documenting drug patents. The panel previously determined that the company had incorrectly listed its patents, prompting Teva’s appeal for further review. For more details, you can read the article on Law360.